We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Single Tube PCR Identifies Aneuploidies in Embryos

By LabMedica International staff writers
Posted on 25 Jun 2012
A novel test is being developed for genetic abnormalities during pregnancy.

A single tube multiplex polymerase chain reaction (PCR) starting from fetal DNA isolated from the mother’s blood, allows the identification of copy number variations (or aneuploidies) of chromosomes 21, 18, 13, X and Y. More...
Such variations cause genetic diseases like Down’s syndrome, Edward’s syndrome, Patau syndrome, triple X syndrome, and Klinefelter’s syndrome.

The test needs only a blood sample, in contrast to the invasive screening methods in use today. It will be based on Multiplicom’s (Niel, Belgium) proprietary MASTR (Multiplex Amplification of Specific Targets for Resequencing) workflow.

The noninvasive aneuploidy testing (NIAT) is a novel approach that aims to replace the 250,000 invasive procedures such as amniocentesis and chorionic villus sampling performed annually in Europe. These procedures are time consuming and carry a significant risk of complications during pregnancy. NIAT is not only rapid and safe but is designed to have predictive power superior to that of conventional prenatal testing methods.

Multiplicom, a molecular diagnostics company specializing in the design, development, production, and commercialization of innovative molecular genetic tests based on massively parallel sequencing, has been awarded a USD 260,000 grant from the Flemish agency for Innovation by Science and Technology (IWT).

The grant is intended to support the development of a novel test for genetic abnormalities during pregnancy that needs only a blood sample, in contrast to the invasive screening methods in use today. The test will be based on Multiplicom’s proprietary MASTR (Multiplex Amplification of Specific Targets for Resequencing) workflow.

Dr. Dirk Pollet, CEO of Multiplicom, said: “This grant is a strong endorsement of our MASTR technology. It will allow Multiplicom to develop a new assay that will help physicians and patients enhance prenatal medical care while cutting costs. In the future, we see this test entirely replacing current invasive techniques.”

Subsequent validation studies will be conducted in close collaboration with hospitals throughout Europe. Multiplicom aims to make the test available to all accredited genetics labs as part of its drive to make personalized healthcare available to all.

Related Links:

Multiplicom




Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Ketosis and DKA Test
D-3-Hydroxybutyrate (Ranbut) Assay
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Pathology

view channel
Image: The AI tool advances precision diagnostics by linking genetic mutations directly to disease types (Photo courtesy of Shutterstock)

AI Tool Simultaneously Identifies Genetic Mutations and Disease Type

Interpreting genetic test results remains a major challenge in modern medicine, particularly for rare and complex diseases. While existing tools can indicate whether a genetic mutation is harmful, they... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.